Strides Pharma falls 5% from 52-week highs on spin off of CDMO
Strides Pharma shareholders would receive 1 share of OneSource for every 2 shares of Strides in the swap ratio of 1:2
Stay updated with breaking news from Contract Development. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Strides Pharma shareholders would receive 1 share of OneSource for every 2 shares of Strides in the swap ratio of 1:2
Strides Pharma Science on Monday said it would spin off its contract development and manufacturing organisation (CDMO) and soft gelatin business into a new entity which would list in the next 12-16 months.
Demerger will be completed by April 1, 2024 according to the stock exchange filing
SAN DIEGO and GAINESVILLE, Ga., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO” or “Societal”; NASDAQ: SCTL), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that the company will participate at the RBC Capital Markets Virtual CDMO Conference. David Enloe, chief executive officer, will be the featured speaker in a fireside
Glenmark Pharmaceuticals has entered into a share purchase agreement with Nirma Limited to divest a 75% stake in Glenmark Lifesciences at a price of Rs 615 per share.